Hypercalcaemia References

  1. Roemer-Bécuwe C, Vigano A, Romano F, Neumann C, Hanson J, Quan HK, Walker P. Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration. J Pain Symptom Manage. 2003 Sep;26(3):843-8. doi: 10.1016/s0885- 3924(03)00252-5
  2. Walker P, Watanabe S, Lawlor P, Hanson J, Pereira J, Bruera E. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol. 1997 Sep;8(9):915-6. doi: 10.1023/a:1008274608267
  3. Ramdany H, Curtin J, Howard P. Zoledronic acid by subcutaneous infusion in palliative medicine. BMJ Support Palliat Care. 2022 Sep 13:spcare-2022-003878. doi: 10.1136/spcare-2022-003878. Epub ahead of print.

Disclaimer (SPAGG - Rewrite)

This Guide is intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.

Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.

While WMPCPS takes every care to compile accurate information , we cannot guarantee its correctness and completeness and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.